Detection of Anti‐Non‐α‐Gal Xenoreactive Antibodies in Human Blood Products
Xenotransplantation · 2025
DOI: 10.1111/xen.70034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Xenotransplantation, 2025. Verfasst von Joseph M Ladowski und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Duke Transplant Center, Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Antibodies, Heterophile, Transplantation, Heterologous. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
Abstract (Originalsprache)
Background
Surgical bleeding is a risk in any solid organ transplant, and is commonly addressed with the transfusion of human blood products to replace or supplement coagulation factors. It is unknown if these blood products would harm xenotransplanted pig organs in human recipients demonstrating coagulopathy. The aim of this study was to investigate in vitro if blood products such as fresh frozen plasma (FFP) or cryoprecipitate (cryo) contain xenoantibodies capable of cytotoxicity to GTKO pig cells.
Methods
We obtained 12 individual single‐donor (7 FFP and 5 cryo) blood products from our institution's blood bank for testing. Peripheral blood mononuclear cells (PBMCs) were obtained from a GTKO/hCD55 pig for use as target cells. We performed a series of flow cytometry crossmatch (FCXM) and complement‐dependent cytotoxicity (CDC) assays.
Results
We found that all the tested blood products contained some degree of IgM and IgG xenoantibody. Tests using a 1:50 dilution revealed a significant decrease in IgM xenoantibody binding, but an increase in the detection of IgG binding. Multiple preparations were capable of GTKO PBMC cytotoxicity but the level of antibody binding and cell death varied by preparation.
Conclusions
Both FFP and cryo contain IgM and IgG non‐galactose‐α‐1,3‐galactose (αGal) xenoantibodies capable of killing GTKO PBMCs, though the level varies by preparation. Although some centers utilize a genetic background with mutations in the three enzymes responsible for the known xenoantigens, others are investigating the GTKO pig as a potential option. These results suggest that a center pursuing a human xenotransplantation study with a GTKO genetic background should pre‐screen blood products prior to administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Duke Transplant Center, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
- Clinical Transplantation Immunology Laboratory, Duke University School of Medicine, Durham, North Carolina, USA.
Förderung
- NIH HHS
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health
- American Society of Transplant Surgeons
Zitieren
APA
Ladowski, J. M., Hu, M., Yoon, J., Chen, Z., Knechtle, S., Jackson, A. M., & Kwun, J. (2025). Detection of Anti‐Non‐α‐Gal Xenoreactive Antibodies in Human Blood Products. Xenotransplantation. https://doi.org/10.1111/xen.70034
Vancouver
Ladowski JM, Hu M, Yoon J, Chen Z, Knechtle S, Jackson AM, et al. Detection of Anti‐Non‐α‐Gal Xenoreactive Antibodies in Human Blood Products. Xenotransplantation. 2025. doi:10.1111/xen.70034
BibTeX
@article{Ladowski2025,
author = {Ladowski, Joseph M and Hu, Meghan and Yoon, Janghoon and Chen, Zheng and Knechtle, Stuart and Jackson, Annette M and Kwun, Jean},
title = {Detection of Anti‐Non‐α‐Gal Xenoreactive Antibodies in Human Blood Products},
journal = {Xenotransplantation},
year = {2025},
doi = {10.1111/xen.70034}
}
EUVIMED